Action Maxpro Capital Acquisition - JMAC

Maxpro Capital Acquisition Corporation (JMAC) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

10,81

( - )

Prix Achat

10,80

Prix Vente

12,05

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

10,81

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Taipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced...

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

TAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced...

Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative...

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced...

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Taipei City, Oct. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced...

Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.

– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

JMAC - Frequently Asked Questions (FAQ)

What is the current Maxpro Capital Acquisition Corporation share price?

The current share price of Maxpro Capital Acquisition Corporation is US$ 10,81

What is the 1 year trading range for Maxpro Capital Acquisition Corporation share price?

Maxpro Capital Acquisition Corporation has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Maxpro Capital Acquisition Corporation (JMAC)

Maxpro Capital Acquisition Corporation (JMAC) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

JMAC Dernières nouvelles

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.

Maxpro Capital Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants

Maxpro Capital Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Maxpro Capital Acquisition Corp. Announces Pricing of $90,000,000 Initial Public Offering

JMAC - Frequently Asked Questions (FAQ)

JMAC Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Maxpro Capital Acquisition Corporation (JMAC)

Maxpro Capital Acquisition Corporation (JMAC) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

JMAC Dernières nouvelles

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.

Maxpro Capital Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants

Maxpro Capital Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Maxpro Capital Acquisition Corp. Announces Pricing of $90,000,000 Initial Public Offering

JMAC - Frequently Asked Questions (FAQ)

JMAC Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS